Australian researchers win $2 million

November 27, 2006

Two young researchers have each been awarded $1 million in funding for biomedical research in Australia. The Pfizer Australia Research Fellowships were presented by Federal Parliamentary Secretary for Health, Christopher Pyne, and Nobel Laureate, Dr Robin Warren, in Sydney on Wednesday.

Queensland's Dr Denise Doolan and Victorian Dr Stephen Turner will receive five years of funding through the Fellowships.

Dr Turner is a lecturer and National Health and Medical Research Council(NHMRC) RD Wright Research Fellow in the Department of Microbiology and Immunology at the University of Melbourne. His research involves the study of how a subset of white blood cells (called killer T cells), recognise and remove infected cells from an individual.

A special interest is how immune memory is generated and how this can protect an individual against infection. His research has implications for improving vaccine strategies for diseases such as HIV/AIDS, pandemic influenza, malaria and some types of cancer.

Dr Doolan is a visiting scientist at the Queensland Institute of Medical Research (QIMR).

She is also currently the Scientific Director of the Malaria Program, Naval Medical Research Center (NMRC), in Silver Spring, USA.

Her research focuses on the field of malaria - specifically, developing vaccines against malaria, understanding the molecular basis of immunity to malaria, and translating Plasmodium falciparum genomic sequence data for practical application.

The Fellowship will allow Dr Doolan to resume her academic career in Australia after studying in the US.

Pfizer Australia has allocated $11 million in funding to Australian scientists since the Pfizer Australia Research Fellowships were established in 2003.

Through this significant financial support of science, the Fellowships aim to encourage leaders in biomedical research to establish a career in Australia, fostering the continued development of Australia as a source of world-class scientific innovation and ideas.

Pfizer Australia senior medical director Dr Bill Ketelbey said the Pfizer Australia Research Fellowships support the development of the Australian scientific community and innovative research projects.

"Australia has benefited significantly from having a strong and internationally competitive scientific community," Dr Bill Ketelbey said. "Continued investment in this valuable resource is essential to the future progress of Australian research."

Pfizer Australia is the nation's leading research-based health care company. It discovers, develops, manufactures and markets innovative medical treatments for both humans and animals. Pfizer Australia is investing more than $45 million in local research and development. For more information visit

Adrian Dolahenty, Pfizer Australia Media Affairs on (0438) 656 175.

Craig Regan, Pfizer Australia Media Affairs on (0408) 448 527.


Pfizer Australia Health Report:

Research Australia

Related Malaria Articles from Brightsurf:

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

Read More: Malaria News and Malaria Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to